Liquid Biopsy Test Helping Select People with Advanced Prostate Cancer for Phase 2 Study of Pamiparib

Liquid Biopsy Test Helping Select People with Advanced Prostate Cancer for Phase 2 Study of Pamiparib
A Phase 2 trial testing the investigational PARP inhibitor pamiparib in treating metastatic castration-resistant prostate cancer patients is using Epic Sciences' novel liquid biopsy assay to select those patients who are most likely to benefit from treatment, the company announced. Epic's test is designed to collect circulating tumor cells from a simple blood draw. Cells are then counted and examined for defects in DNA repair, which makes them more responsive to PARP inhibitors like pamiparib. In cancer, major chromosomal alterations that lead to poor prognosis, cancer spread, and treatment resistance are often associated with defects in one of the mechanisms of DNA repair – called homologous recombination. Epic examines circulating tumor cells (CTCs) for homologous recombination deficiency (HRD) by simply looking into major alterations in chromosomal number and size – a feature called chromosomal instability. "This is the first assay to measure chromosomal instability using circulating tumor cells and digital pathology [a technology that converts microscopy samples into digital data], opening up tremendous opportunities for developers of anticancer PARP inhibitors to improve patient selection in clinical trials," Ryan Dittamore, chief of medical innovation at Epic Sciences, said in a
Subscribe or to access all post and page content.